title: HSV antivirals - current and future treatment options.
abstract: Herpes simplex virus (HSV) types 1 and 2 can cause infections with clinical manifestations ranging from benign and generally self-limiting blisters or sores as seen in labial and genital herpes through to severe and in rare cases even life-threatening infections. At present, approved treatments for herpes simplex virus are almost all nucleoside analogs. Novel antiviral approaches include therapeutic vaccines, with the most advanced having successfully completed Phase 2 clinical development. Moreover, several small molecules approaches are being developed for the treatment of genital or labial HSV infections. Of particular interest are two novel compounds (amenamevir and pritelivir) belonging to the new class of helicase-primase inhibitors with promising Phase 2 data.
authors.affiliation: AiCuris Anti-infective Cures GmbH, Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Birkmann
authors.affiliation: AiCuris Anti-infective Cures GmbH, Germany. Electronic address: holger.zimmermann@aicuris.com.
authors.forename: Holger
authors.initials: H
authors.lastname: Zimmermann
mesh_terms: D000212:Acyclovir / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D004265:DNA Helicases / Q000037:antagonists & inhibitors; D019915:DNA Primase / Q000037:antagonists & inhibitors; D024882:Drug Resistance, Viral; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000821:virology; D006561:Herpes Simplex / Q000188:drug therapy* / Q000517:prevention & control / Q000821:virology*; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D018259:Herpesvirus 1, Human / Q000187:drug effects; D018258:Herpesvirus 2, Human / Q000187:drug effects; D006801:Humans; D010069:Oxadiazoles / Q000009:adverse effects / Q000627:therapeutic use; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use; D013449:Sulfonamides; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D014764:Viral Proteins / Q000187:drug effects
chemical_list: C568714:ASP2151; D000998:Antiviral Agents; D022301:Herpes Simplex Virus Vaccines; D010069:Oxadiazoles; D011725:Pyridines; D013449:Sulfonamides; D013844:Thiazoles; D014764:Viral Proteins; C453221:pritelivir; D019915:DNA Primase; D004265:DNA Helicases; D000212:Acyclovir